The scale of the registry’s achievement is itself noteworthy. Established in 2000 and coordinated since 2010 by the National Cancer Institute within Argentina’s Ministry of Health, ROHA has now registered more than 41,000 childhood cancer cases over its lifetime, with estimated national coverage exceeding 90 percent of children under 15. For the new analysis, researchers extracted 31,241 cases of malignant tumors diagnosed between January 2000 and December 2022 in children younger than 15 who were resident in Argentina at the time of diagnosis, an average of roughly 1,350 new cases each year. Adolescents aged 15 to 19 were excluded because registry coverage for that age group remains too incomplete to yield reliable estimates, a limitation the authors acknowledge openly.

On the question of how often childhood cancer occurs, the answer proved remarkably stable. The age-standardized incidence rate across the full study period was 131 cases per million children per year, and joinpoint regression analysis found essentially no significant overall trend, with an average annual percent change of just 0.1 percent. That figure sits comfortably within the range reported by population-based registries across Latin America and remains lower than rates observed in many high-income countries, where rising incidence has often been attributed to improved diagnostic capacity and evolving classification systems rather than any true increase in disease. Within the overall stability, however, the data revealed subtle shifts: significant increases in central nervous system tumors, malignant bone tumors, and epithelial neoplasms and melanomas, alongside significant declines in lymphomas and kidney tumors. The authors caution that some of these movements may reflect greater access to neuroimaging and diagnostic intensity rather than genuine changes in disease frequency.

The survival story is where the registry’s long memory pays off most dramatically. Five-year overall survival for all childhood cancers combined rose steadily across successive diagnostic periods, from 59.7 percent for children diagnosed in 2000 through 2004, to 65.5 percent in 2005 through 2009, 70.0 percent in 2010 through 2014, and 70.9 percent in the most recent period, 2015 through 2019. The improvement was statistically robust, and the largest gains were concentrated in leukemias and central nervous system tumors, two of the most common and historically most lethal categories of childhood malignancy. Leukemia survival climbed from 59.1 percent in the earliest period to 71.8 percent in the latest, while survival for brain and other central nervous system tumors jumped from 45.3 percent to 62.1 percent, a transformation reflecting advances in risk stratification, treatment protocols, and supportive care.

Not every tumor type shared equally in the progress. Survival for lymphomas reached 86.4 percent and retinoblastoma, a cancer of the eye, an exceptional 94.1 percent in the most recent period, figures that approach international benchmarks. But tumors demanding highly specialized multidisciplinary management, including neuroblastoma, malignant bone tumors, soft tissue sarcomas, and hepatic tumors, showed limited or inconsistent gains. Neuroblastoma survival actually dipped to 58.8 percent in the latest period after reaching 62.8 percent previously. More troubling still, the overall survival curve appears to have plateaued: the difference between the 2010 through 2014 and 2015 through 2019 estimates is small, with overlapping confidence intervals. The researchers interpret this plateau as a signal that further progress will depend less on refining existing protocols and more on equitable access to high-complexity diagnostics, precision therapies, and robust health system infrastructure.

That infrastructure, the analysis makes clear, is unevenly distributed across Argentina’s vast territory. The country is divided into five major geographic regions, and survival differs sharply among them. The Central Region, which concentrates the nation’s population, wealth, and high-complexity pediatric hospitals, recorded the highest five-year survival at 72.0 percent, closely followed by the Southern Region at 71.9 percent. At the other extreme, the Northwest Region posted a five-year survival of just 63.3 percent. The gap between the best and worst performing regions approaches the differences observed between some middle-income and high-income countries, a striking illustration of how national averages can conceal profound internal inequities in access and outcomes.

Socioeconomic gradients reinforce the geographic ones. When provinces were grouped by the United Nations Development Programme’s Human Development Index, children in low-HDI provinces saw five-year survival improve from 57.4 percent in 2000 through 2009 to 68.1 percent in 2010 through 2019, while those in high-HDI provinces moved from 64.2 percent to 73.1 percent. In other words, every socioeconomic group made substantial gains, but the gap between richest and poorest provinces narrowed only modestly, from roughly seven percentage points to five. The authors stress that these comparisons are descriptive rather than causal, and that provincial HDI may not capture individual family circumstances, but the pattern is consistent with international evidence linking socioeconomic status to treatment completion and survival.

Understanding why these disparities persist requires looking at the structure of Argentine pediatric oncology itself. The health system is fragmented into public, social security, and private sectors, with care largely decentralized to the provinces. About 80 percent of children with cancer rely on the public sector, and treatment is delivered through a heterogeneous network of 31 pediatric oncology units of varying complexity. Care is intensely centralized: three high-complexity hospitals in Buenos Aires manage nearly half of all cases, and the national pediatric hospital alone receives more than 500 new oncology patients annually. As a result, approximately 48 percent of children must migrate between provinces for partial or complete treatment, a structural feature that introduces delays, administrative barriers, and fragmented shared-care arrangements. Regions in the north and south lack maximum-complexity services for some tumors, and supportive care resources such as pediatric intensive care, specialized nursing, and management of severe infections remain uneven, with infectious complications still an important cause of death among children with leukemia.

Against these challenges, Argentina has also built something distinctive: a legal and policy architecture that fuses cancer surveillance with social protection. Since 2023, case reporting has been mandatory under the Childhood and Adolescent Cancer Protection Law, Law No. 27.674, which introduced the Unique Pediatric Oncology Certificate, linking registry data directly to access for health, economic, and social benefits. The registry thus functions not merely as an epidemiological instrument but as the backbone of a rights-based system that can support treatment coverage, transportation assistance, and continuity of care for families forced to migrate. Philanthropic foundations and parent organizations complement public services by funding accommodation, transport, and psychosocial support. The authors note that the formal impact of the new law and certificate has not yet been evaluated, making this a priority for future health services research.

The international context sharpens the significance of these numbers. Argentina’s five-year survival of 70.9 percent is among the highest reported in population-based studies from Latin America, comparable to Brazil and Mexico and above several regional peers, though still below Chile and Uruguay, and well short of the 80 to 85 percent achieved in high-income countries. Crucially, the country has already surpassed the 60 percent survival target set by the WHO Global Initiative for Childhood Cancer. Meanwhile, national mortality data tell a consistent story: the age-standardized childhood cancer death rate fell from 4.56 per 100,000 children in 1999 through 2000 to 3.73 in 2021 through 2022, a significant annual decline of 1.9 percent that mirrors the survival gains. For middle-income countries wrestling with how to close the childhood cancer gap, Argentina’s quarter-century experiment suggests a replicable formula: sustained, high-coverage registration, honest measurement of internal inequities, and the political will to bind data to social protection. The remaining challenge, the authors conclude, is ensuring that the next decade of gains reaches the children in the northwest provinces who still face the longest odds.

Subject of Research: Long-term trends in childhood cancer incidence, survival, and mortality in Argentina based on the national pediatric oncology registry

Article Title: Childhood cancer incidence, survival and mortality patterns in Argentina, 2000–2022: from the Argentine Oncopediatric Registry (ROHA)

Article References: Moreno, F., Chaplin, M. A., Nana, M., & Abriata, M. G. (2026). Childhood cancer incidence, survival and mortality patterns in Argentina, 2000–2022: from the Argentine Oncopediatric Registry (ROHA). Frontiers in Cancer Control and Society, 4, Article 1844383. https://doi.org/10.3389/fcacs.2026.1844383

Image Credits: AI Generated

DOI: 10.3389/fcacs.2026.1844383

Keywords: childhood cancer, Argentina, ROHA registry, cancer survival, health disparities, pediatric oncology, cancer incidence, mortality trends, Latin America, health policy, Human Development Index, cancer surveillance